<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-159922" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Buprenorphine and Naloxone</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Togioka</surname>
            <given-names>Brandon M.</given-names>
          </name>
          <aff>Oregon Health &#x00026; Science University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Brandon Togioka declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-159922.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">
<bold>FDA-Approved Indications</bold>
</p>
        <p>Buprenorphine and naloxone (buprenorphine-naloxone) combination is Food and Drug Administration (FDA)&#x02013;approved for detoxification from opioids and maintenance therapy for opioid use disorder.<xref ref-type="bibr" rid="article-159922.r1">[1]</xref>&#x000a0;The Drug Addiction Treatment Act made it legal for&#x000a0;clinicians to prescribe Schedule III drugs, such as buprenorphine-naloxone, for the treatment of opioid use disorder.<xref ref-type="bibr" rid="article-159922.r2">[2]</xref><xref ref-type="bibr" rid="article-159922.r3">[3]</xref>&#x000a0;Buprenorphine-naloxone was the first medication approved for outpatient treatment of opioid use disorder by the Drug Addiction and Treatment Act (2000).<xref ref-type="bibr" rid="article-159922.r1">[1]</xref><xref ref-type="bibr" rid="article-159922.r3">[3]</xref>&#x000a0;The sublingual tablet was FDA-approved to treat opioid use disorder in 2002.<xref ref-type="bibr" rid="article-159922.r1">[1]</xref></p>
        <p>Opioid use disorder is defined by a strong motivation to obtain and use opioids in the face of significant detrimental effects on an individual&#x02019;s health, professional life, and relationships.<xref ref-type="bibr" rid="article-159922.r2">[2]</xref>&#x000a0;Buprenorphine-naloxone is a partial agonist used for substitution therapy, wherein the drug is prescribed to decrease craving and the frequency of use of full mu receptor agonists (eg, heroin, fentanyl).<xref ref-type="bibr" rid="article-159922.r3">[3]</xref><xref ref-type="bibr" rid="article-159922.r4">[4]</xref>&#x000a0;Substitution therapy decreases the intensity of euphoria from opioid agonism and reduces the incidence of adverse effects. Buprenorphine-naloxone is associated with greater retention in drug treatment programs, a lower frequency of relapse, and less opioid-related overdose than placebo.<xref ref-type="bibr" rid="article-159922.r5">[5]</xref></p>
        <p>Alpha-2 agonists are also used to treat opioid use disorder. Buprenorphine-naloxone is associated with greater suppression of symptoms of opioid withdrawal than the &#x003b1;-2 agonists clonidine and lofexidine.<xref ref-type="bibr" rid="article-159922.r6">[6]</xref>&#x000a0;Patients&#x000a0;prescribed buprenorphine-naloxone remain in treatment for a longer duration of time, and the adverse effects of treatment appear to be less intense with buprenorphine-naloxone compared to &#x003b1;-2 agonists.<xref ref-type="bibr" rid="article-159922.r6">[6]</xref><xref ref-type="bibr" rid="article-159922.r7">[7]</xref>&#x000a0;Additionally, treatment success, defined as urine samples that are free of illicit opioids, is higher in patients on buprenorphine-naloxone than clonidine.<xref ref-type="bibr" rid="article-159922.r8">[8]</xref></p>
        <p>Methadone is another FDA-approved medication for detoxification and maintenance treatment of opioid use disorder. When compared with methadone, buprenorphine-naloxone has a superior safety profile, enabling at-home adherence. This is a significant advantage over methadone, which requires daily administration in a specially approved clinic. Accordingly, buprenorphine-naloxone is preferred for patients who do not live near a methadone clinic or who have transportation challenges. An additional advantage of buprenorphine-naloxone is the duration of the induction period. Buprenorphine-naloxone can be titrated to a maintenance dose over a few days. Methadone induction requires weeks to months to reach the maintenance dose.</p>
        <p>Methadone is a full mu receptor agonist with a long duration of action. Methadone has a narrower therapeutic index and is more likely to cause respiratory depression.<xref ref-type="bibr" rid="article-159922.r9">[9]</xref>&#x000a0;Buprenorphine-naloxone appears to have a similar capacity to diminish symptoms of opioid withdrawal, is associated with a similar incidence of adverse effects, and is noninferior to methadone for preventing relapse.<xref ref-type="bibr" rid="article-159922.r6">[6]</xref><xref ref-type="bibr" rid="article-159922.r10">[10]</xref><xref ref-type="bibr" rid="article-159922.r11">[11]</xref><xref ref-type="bibr" rid="article-159922.r12">[12]</xref>&#x000a0;As a partial mu-opioid receptor agonist, buprenorphine is associated with less feelings of euphoria than methadone, which may contribute to a lower abuse rate. However, some patients experience greater suppression of cravings on methadone than buprenorphine-naloxone due to full mu receptor agonism.<xref ref-type="bibr" rid="article-159922.r12">[12]</xref>&#x000a0;According to the CDC 2022 guidelines, a clinical trial indicated no discernible disparity between buprenorphine-naloxone and methadone concerning study retention, pain, functional outcomes, or self-reported adverse effects.<xref ref-type="bibr" rid="article-159922.r13">[13]</xref><bold>&#x000a0;</bold>The decision regarding buprenorphine-naloxone versus methadone for opioid use disorder treatment should&#x000a0;account for the patient&#x02019;s medications, the likelihood of drug-drug interactions, the presence of cardiac conduction defects such as prolonged QT syndrome, and patient preference.<xref ref-type="bibr" rid="article-159922.r1">[1]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Buprenorphine-naloxone is used off-label to treat chronic pain. While buprenorphine has a ceiling effect for respiratory depression, a ceiling effect does not appear to exist for analgesia.<xref ref-type="bibr" rid="article-159922.r14">[14]</xref><xref ref-type="bibr" rid="article-159922.r15">[15]</xref>&#x000a0;Additionally, buprenorphine is associated with a lower risk of diversion and physical dependence than commonly prescribed opioids due to the&#x000a0;partial agonism effect at the mu receptor.<xref ref-type="bibr" rid="article-159922.r16">[16]</xref><xref ref-type="bibr" rid="article-159922.r17">[17]</xref></p>
        <p>Buprenorphine-naloxone&#x000a0;is used off-label to treat acute pain in the perioperative period. The duration of analgesia from buprenorphine is&#x000a0;6 to&#x000a0;8 hours; however, it is administered once per day when prescribed for substitution therapy. Accordingly, when used for acute pain management, there may be an advantage to dividing the daily dose into&#x000a0;3 or&#x000a0;4 smaller aliquots for daily administration.<xref ref-type="bibr" rid="article-159922.r2">[2]</xref></p>
        <p>Buprenorphine&#x000a0;is used off-label to treat methadone-induced respiratory depression in the emergency room. In 1 study comparing buprenorphine and titrated doses of naloxone, buprenorphine was associated with a higher frequency of arousal to normal consciousness, a lower incidence of recurrence of respiratory depression, and a lower severity of opioid withdrawal symptoms.<xref ref-type="bibr" rid="article-159922.r18">[18]</xref></p>
      </sec>
      <sec id="article-159922.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Buprenorphine-naloxone is&#x000a0;an effective and commonly prescribed combination medication created to treat opioid use disorder.</p>
        <p>
<bold>Mechanism</bold>
</p>
        <p>Buprenorphine is a long-acting opioid that possesses a strong binding coefficient at the mu receptor.<xref ref-type="bibr" rid="article-159922.r19">[19]</xref>&#x000a0;A buprenorphine dose of 4 mg per day will bind approximately 50% of mu-opioid receptors, which is sufficient to suppress opioid withdrawal symptoms.<xref ref-type="bibr" rid="article-159922.r20">[20]</xref>&#x000a0;A buprenorphine dose of 16 mg will bind approximately 80% of mu-opioid receptors and is sufficient to block the euphoric effects of most abused opioids.<xref ref-type="bibr" rid="article-159922.r20">[20]</xref>&#x000a0;Buprenorphine&#x02019;s slow dissociation kinetics and strong binding affinity can prevent full mu receptor activation by more potent opioids.<xref ref-type="bibr" rid="article-159922.r3">[3]</xref><xref ref-type="bibr" rid="article-159922.r21">[21]</xref>&#x000a0;This can prevent opioid-induced respiratory depression and apnea when large doses of full mu receptor agonists, such as fentanyl or heroin, are taken by individuals on buprenorphine-naloxone.<xref ref-type="bibr" rid="article-159922.r21">[21]</xref></p>
        <p>Buprenorphine is a weak antagonist of the opioid kappa and delta receptors, an agonist of the opioid receptor-like-1 protein, and a nociception protein receptor activator.<xref ref-type="bibr" rid="article-159922.r14">[14]</xref><xref ref-type="bibr" rid="article-159922.r16">[16]</xref>&#x000a0;Nociception protein receptor activation stimulates breathing, causes bradycardia and hypotension, and has varying effects on pain perception, from antinociception to hyperalgesia, depending upon the level of nervous system activation.<xref ref-type="bibr" rid="article-159922.r22">[22]</xref>&#x000a0;Despite&#x000a0;a high binding affinity, buprenorphine only partially activates the mu receptor.<xref ref-type="bibr" rid="article-159922.r14">[14]</xref>&#x000a0;The combination of buprenorphine&#x02019;s partial agonism at the mu receptor and nociception protein receptor activation decreases the probability that buprenorphine will cause a critical respiratory event in contrast to full mu receptor activation by opioids such as fentanyl, hydromorphone, oxycodone, and morphine.<xref ref-type="bibr" rid="article-159922.r21">[21]</xref></p>
        <p>Naloxone is a pure opioid receptor antagonist combined with buprenorphine to reduce abuse potential.<xref ref-type="bibr" rid="article-159922.r3">[3]</xref>&#x000a0;Naloxone competes and displaces other opioids from the mu, kappa, and delta receptors, diminishing their effects.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Significant interindividual variability is seen with buprenorphine absorption. One study in healthy volunteers found that the bioavailability of sublingually administered buprenorphine was approximately 30%.<xref ref-type="bibr" rid="article-159922.r23">[23]</xref>&#x000a0;The coadministration of naloxone with buprenorphine is not associated with reducing buprenorphine bioavailability.<xref ref-type="bibr" rid="article-159922.r24">[24]</xref>&#x000a0;The mean time to peak plasma concentration after sublingual buprenorphine is between 40 and 210 minutes.<xref ref-type="bibr" rid="article-159922.r25">[25]</xref>&#x000a0;When naloxone is administered sublingually, it has a clinically negligible effect.<xref ref-type="bibr" rid="article-159922.r26">[26]</xref><xref ref-type="bibr" rid="article-159922.r27">[27]</xref>&#x000a0;The bioavailability of sublingually administered naloxone is uncertain, but the best evidence is that it is &#x0003c;10%.<xref ref-type="bibr" rid="article-159922.r24">[24]</xref>&#x000a0;However, if naloxone is disintegrated via incorporation into a solvent and injected into a vein, naloxone blocks mu receptor activation, precipitating symptoms of opioid withdrawal.<xref ref-type="bibr" rid="article-159922.r26">[26]</xref><xref ref-type="bibr" rid="article-159922.r28">[28]</xref></p>
        <p><bold>Distribution:</bold>&#x000a0;Buprenorphine has high plasma binding to &#x003b1;- and &#x003b2;-globulins (96%) and a distribution volume significantly greater than adult human physiologic volumes (200 to 300 L).<xref ref-type="bibr" rid="article-159922.r25">[25]</xref>&#x000a0;The volume of naloxone distribution after sublingual administration has not been extensively studied. After intravenous (IV) administration, naloxone exhibits weak binding to plasma proteins and has a large volume of distribution (200 L).<xref ref-type="bibr" rid="article-159922.r29">[29]</xref></p>
        <p><bold>Metabolism:</bold>&#x000a0;Buprenorphine undergoes significant first-pass metabolism (hepatic extraction ratio close to 1) when&#x000a0;administered orally, which means a significant proportion of the medication is&#x000a0;metabolized in the liver.<xref ref-type="bibr" rid="article-159922.r3">[3]</xref><xref ref-type="bibr" rid="article-159922.r25">[25]</xref>&#x000a0;Accordingly, the preferred method of administration is sublingual, bypassing the first-pass effect.<xref ref-type="bibr" rid="article-159922.r3">[3]</xref>&#x000a0;The plasma half-life of buprenorphine-naloxone when taken sublingually is 38 hours.<xref ref-type="bibr" rid="article-159922.r4">[4]</xref>&#x000a0;Buprenorphine is metabolized primarily by the cytochrome P450 3A4 enzyme.<xref ref-type="bibr" rid="article-159922.r3">[3]</xref>&#x000a0;After&#x000a0;IV administration, naloxone undergoes rapid hepatic metabolism with a hepatic extraction ratio of 0.8.<xref ref-type="bibr" rid="article-159922.r30">[30]</xref>&#x000a0;The elimination half-life of naloxone after&#x000a0;IV administration is between 30 minutes and 90 minutes.<xref ref-type="bibr" rid="article-159922.r29">[29]</xref></p>
        <p><bold>Excretion:&#x000a0;</bold>After sublingual administration, approximately 10% to 30% of buprenorphine and its metabolites are excreted in urine in the conjugated form, with the remainder excreted in feces in the free form.<xref ref-type="bibr" rid="article-159922.r25">[25]</xref>&#x000a0;After&#x000a0;IV administration, approximately 60% of naloxone and its metabolites are excreted in the urine in the conjugated form.<xref ref-type="bibr" rid="article-159922.r29">[29]</xref>&#x000a0;The excretion of naloxone after sublingual administration has not been studied.</p>
      </sec>
      <sec id="article-159922.s3" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms</bold>
</p>
        <p>FDA-approved formulations of buprenorphine-naloxone include the sublingual tablet, sublingual film, and buccal film.<xref ref-type="bibr" rid="article-159922.r1">[1]</xref><xref ref-type="bibr" rid="article-159922.r3">[3]</xref>&#x000a0;The buccal film is no longer available in the United States.</p>
        <p>
<bold>Strength</bold>
</p>
        <p>The ratio of buprenorphine to naloxone in the sublingual film is 4:1, or 4 mg buprenorphine/1 mg naloxone. The sublingual film is available in strengths of 2&#x000a0;mg buprenorphine/0.5 mg naloxone, 4 mg buprenorphine/1 mg naloxone, 8 mg buprenorphine/2 mg naloxone, and 12 mg buprenorphine/3 mg naloxone.</p>
        <p>The ratio of buprenorphine to naloxone in the sublingual tablet is approximately 4:1, or 4 mg buprenorphine/1 mg naloxone.<xref ref-type="bibr" rid="article-159922.r27">[27]</xref>&#x000a0;The sublingual tablet is available in strengths of 0.7 mg buprenorphine/0.18 mg naloxone, 1.4 mg buprenorphine/0.36 mg naloxone, 2.9 mg buprenorphine/0.71 mg naloxone, 5.7 mg buprenorphine/1.4 mg naloxone, 8.6 mg buprenorphine/2.1 mg naloxone and 11.4 mg buprenorphine/2.9 mg naloxone.</p>
        <p>
<bold>Adult Dose</bold>
</p>
        <p>Before initiating buprenorphine-naloxone, patients with opioid use disorder undergo a period of abstinence and begin to experience mild opioid withdrawal symptoms. For most patients withdrawing from heroin, oxycodone, or fentanyl, a period of 12 hours is sufficient to provoke symptoms of mild withdrawal. Initiation of buprenorphine-naloxone during an inpatient admission may be associated with&#x000a0;higher treatment retention.<xref ref-type="bibr" rid="article-159922.r31">[31]</xref>&#x000a0;However, buprenorphine-naloxone may be initiated safely at home, in a medical clinic, or in an acute care hospital.<xref ref-type="bibr" rid="article-159922.r32">[32]</xref>&#x000a0;There is no limit to the duration of therapy. Some experts believe that indefinite treatment reduces the risk of relapse. Additionally, all-cause mortality is decreased compared to when&#x000a0;patients&#x000a0;are untreated.<xref ref-type="bibr" rid="article-159922.r33">[33]</xref></p>
        <p>The sublingual film should be placed under the tongue whole without cutting, chewing, or swallowing until complete dissolution occurs.<xref ref-type="bibr" rid="article-159922.r34">[34]</xref>&#x000a0;If more than&#x000a0;1 film is being administered simultaneously, place the second film under the other side of the tongue. After buprenorphine-naloxone has dissolved, take a sip of water, swish it around the oropharyngeal cavity, and swallow. The initial dose of buprenorphine-naloxone is typically 2 mg/.5 to 1 mg to 4 mg/0.5 to 1 mg, respectively. If withdrawal symptoms are present, the dose can be increased from 8 mg to 12 mg/2 mg to 3 mg within the first 24 hours.<xref ref-type="bibr" rid="article-159922.r35">[35]</xref>&#x000a0;Buprenorphine-naloxone is typically titrated over a few days to the therapeutic dose (8 mg to 32 mg/2 mg to 8 mg, respectively) or the dose necessary to reduce cravings and physiological withdrawal symptoms.<xref ref-type="bibr" rid="article-159922.r36">[36]</xref><xref ref-type="bibr" rid="article-159922.r37">[37]</xref>&#x000a0;</p>
        <p>Two meta-analyses found that the 16 mg/day to 32 mg/day dose was associated with greater treatment retention and a lower frequency of illicit opioid use compared to lower dosages.<xref ref-type="bibr" rid="article-159922.r31">[31]</xref><xref ref-type="bibr" rid="article-159922.r38">[38]</xref>&#x000a0;This may be because higher doses of buprenorphine-naloxone are more effective at suppressing cravings than lower doses.<xref ref-type="bibr" rid="article-159922.r39">[39]</xref><xref ref-type="bibr" rid="article-159922.r40">[40]</xref>&#x000a0;However, as per the Substance Abuse and Mental Health Services (SAMHSA), dosages above 24 mg buprenorphine or 24 mg/6 mg buprenorphine/naloxone have no clinical advantage.&#x000a0;</p>
        <p>The initial dose of sublingual tablets is typically 1.4 mg buprenorphine/0.36 mg naloxone. This dosage is equivalent to 2 mg /0.5 mg in the sublingual film. If withdrawal symptoms are present, the dose may increase to 5.7 mg/1.4 mg (equivalent to sublingual 8 mg/4 mg) within the first 24 hours. Like the buprenorphine-naloxone sublingual film, the tablet form can be titrated to the maintenance dose over a few days.&#x000a0;</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Patients with hepatic impairment:&#x000a0;</bold>Buprenorphine and naloxone undergo significant hepatic metabolism. Increased vigilance for adverse effects is recommended in patients with moderate liver dysfunction (Child-Pugh score of&#x000a0;7 to&#x000a0;9 points). Manufacturers of the sublingual film and tablet recommend avoiding the administration of buprenorphine-naloxone in patients with severe liver dysfunction (Child-Pugh score &#x0003e;9). Acute hepatic necrosis after&#x000a0;IV buprenorphine has been reported.<xref ref-type="bibr" rid="article-159922.r41">[41]</xref></p>
        <p><bold>Patients with renal impairment:&#x000a0;</bold>Manufacturers of the sublingual film and tablet do not recommend dosing adjustments for patients with renal impairment.&#x000a0;</p>
        <p><bold>Pregnant patients:&#x000a0;</bold>Pregnancy is not considered a contraindication to buprenorphine-naloxone therapy.<xref ref-type="bibr" rid="article-159922.r42">[42]</xref>&#x000a0;Conversely, untreated opioid use disorder during pregnancy increases the risk for fetal, neonatal, and maternal morbidity.<xref ref-type="bibr" rid="article-159922.r43">[43]</xref>&#x000a0;Substitution therapy is recommended for treating opioid use disorder in pregnancy.<xref ref-type="bibr" rid="article-159922.r44">[44]</xref><xref ref-type="bibr" rid="article-159922.r45">[45]</xref>&#x000a0;Buprenorphine-naloxone and methadone are both appropriate first-line therapies for opioid use disorder during pregnancy.<xref ref-type="bibr" rid="article-159922.r46">[46]</xref>&#x000a0;Substitution therapy does not appear to increase the risk for childhood developmental problems.<xref ref-type="bibr" rid="article-159922.r47">[47]</xref><xref ref-type="bibr" rid="article-159922.r48">[48]</xref>&#x000a0;Human studies have not found an association between buprenorphine-naloxone therapy and gestational age at birth or the prevalence of birth defects.<xref ref-type="bibr" rid="article-159922.r49">[49]</xref><xref ref-type="bibr" rid="article-159922.r50">[50]</xref><xref ref-type="bibr" rid="article-159922.r51">[51]</xref></p>
        <p>Buprenorphine-naloxone crosses the placenta and&#x000a0;is found in the fetal circulation in women taking a daily dose &#x0003e;4 mg/1 mg.&#x000a0;Fetal exposure to naloxone was significantly lower than buprenorphine, with undetectable levels in 45% of infants. Fetal concentrations were highly correlated with maternal drug levels.<xref ref-type="bibr" rid="article-159922.r52">[52]</xref>&#x000a0;Infants born to mothers on buprenorphine-naloxone therapy may experience neonatal withdrawal symptoms such as depressed breathing, irritability, tremors, and convulsions after birth.<xref ref-type="bibr" rid="article-159922.r53">[53]</xref>&#x000a0;Buprenorphine-naloxone may be associated with less severe neonatal abstinence symptoms, greater odds of full-term birth, greater birth weight, and shorter duration of fetal hospitalization than methadone.<xref ref-type="bibr" rid="article-159922.r49">[49]</xref><xref ref-type="bibr" rid="article-159922.r54">[54]</xref><xref ref-type="bibr" rid="article-159922.r55">[55]</xref></p>
        <p><bold>Breastfeeding patients:&#x000a0;</bold>Buprenorphine-naloxone is not contraindicated in women who are breastfeeding; however,&#x000a0;the drug does enter breast milk. Buprenorphine has poor oral availability. Thus, the quantity of buprenorphine that would be expected to enter the infant&#x02019;s systemic circulation is low.<xref ref-type="bibr" rid="article-159922.r56">[56]</xref>&#x000a0;Insufficient data exists regarding the excretion of naloxone into breast milk, but&#x000a0;the limited oral absorption suggests a low likelihood of impacting the breastfed infant.<xref ref-type="bibr" rid="article-159922.r57">[57]</xref><xref ref-type="bibr" rid="article-159922.r58">[58]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>There is a lack of data regarding the use of buprenorphine-naloxone in pediatric patients. The decision to use buprenorphine-naloxone to treat opioid use disorder should be based upon risk-benefit analysis and shared decision-making that includes the clinician and, at times, the patient&#x02019;s family.</p>
        <p><bold>Geriatric patients:&#x000a0;</bold>There is a lack of data regarding the use of buprenorphine-naloxone in geriatric patients. The decision to use buprenorphine-naloxone to treat opioid use disorder should be based upon a risk-benefit analysis that includes consideration of gastrointestinal, neurological, hepatic, renal, cardiac, and dental disease.</p>
        <p><bold>Surgical patients:&#x000a0;</bold>Surgery represents a significant challenge to patients on buprenorphine-naloxone therapy. Patients on buprenorphine-naloxone therapy have increased sensitivity to pain, decreased tolerance of pain, and decreased analgesic effect from opioids, which makes the achievement of adequate postoperative analgesia difficult.<xref ref-type="bibr" rid="article-159922.r59">[59]</xref><xref ref-type="bibr" rid="article-159922.r60">[60]</xref>&#x000a0;Patients on buprenorphine-naloxone therapy may worry about inadequate perioperative analgesia, experiencing unfair treatment, and the temptation to relapse upon hospital discharge.<xref ref-type="bibr" rid="article-159922.r61">[61]</xref></p>
        <p>Buprenorphine-naloxone should be discontinued before surgery. The concern is that postoperative analgesia&#x000a0;is inadequate because buprenorphine can limit the effectiveness of full opioid agonists, which are commonly used to provide postoperative analgesia. This view is supported by case reports of poor-quality postoperative analgesia in patients maintained on buprenorphine.<xref ref-type="bibr" rid="article-159922.r62">[62]</xref><xref ref-type="bibr" rid="article-159922.r63">[63]</xref>&#x000a0;If buprenorphine-naloxone is discontinued the day before surgery, the previous dose can be resumed if the abstinent period is &#x02264;3 days.</p>
        <p>While discontinuation of buprenorphine-naloxone can facilitate easier control of postoperative pain, many&#x000a0;clinicians now advocate for continuing buprenorphine-naloxone maintenance therapy throughout the perioperative period.<xref ref-type="bibr" rid="article-159922.r2">[2]</xref><xref ref-type="bibr" rid="article-159922.r64">[64]</xref>&#x000a0;This strategy avoids anxiety associated with halting buprenorphine-naloxone maintenance therapy, having to rely upon short-acting opioids to treat symptoms of withdrawal, and the difficult transition from full to partial mu receptor agonism after surgery.<xref ref-type="bibr" rid="article-159922.r2">[2]</xref>&#x000a0;Several studies have confirmed that buprenorphine therapy may be continued through the postoperative period without compromising short- or long-term pain relief or adversely affecting long-term outcomes.<xref ref-type="bibr" rid="article-159922.r65">[65]</xref><xref ref-type="bibr" rid="article-159922.r66">[66]</xref></p>
        <p>Buprenorphine-naloxone treatment within the normal therapeutic range (16 mg/4 mg) typically leaves about 20% of mu receptors unoccupied.<xref ref-type="bibr" rid="article-159922.r20">[20]</xref>&#x000a0;These unoccupied mu receptors are available for full receptor agonism when common perioperative opioids, such as fentanyl and hydromorphone, are administered.<xref ref-type="bibr" rid="article-159922.r3">[3]</xref>&#x000a0;Sufentanil may be the preferred opioid in the perioperative period for individuals on buprenorphine-naloxone therapy because it possesses a higher binding affinity than buprenorphine.<xref ref-type="bibr" rid="article-159922.r67">[67]</xref>&#x000a0;There is no evidence that treatment of acute pain after surgery with opioids is associated with a higher likelihood of addiction relapse.<xref ref-type="bibr" rid="article-159922.r68">[68]</xref></p>
        <p>Postoperative multimodal analgesia is recommended for all patients on buprenorphine-naloxone. Patients will not exhibit tolerance to nonopioid analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors, COX-3 inhibitors, pregabalin, gabapentin, &#x003b1;-2 agonists, local anesthetics, and NMDA receptor antagonists such as ketamine.<xref ref-type="bibr" rid="article-159922.r2">[2]</xref>&#x000a0;Regional anesthesia techniques are amongst the most effective methods of treating postoperative pain, and they should be incorporated into the postoperative analgesia plan whenever possible.</p>
      </sec>
      <sec id="article-159922.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Adverse Drug Reactions</bold>
</p>
        <p>The most common adverse effects attributed to buprenorphine-naloxone administration are caused by buprenorphine&#x02019;s ability to uncouple and displace opioids with greater mu receptor agonism, which&#x000a0;may precipitate withdrawal symptoms.<xref ref-type="bibr" rid="article-159922.r28">[28]</xref>&#x000a0;Buprenorphine has a strong binding coefficient at the mu receptor but causes low mu receptor activation. When buprenorphine is administered to a patient&#x000a0;experiencing a euphoric effect from a full mu agonist, such as fentanyl, the level of mu receptor agonism will decrease precipitating symptoms of opioid withdrawal. Symptoms of opioid withdrawal syndrome include pain, irritability, rhinorrhea, nausea, vomiting, abdominal cramping, myalgia, tachycardia, and diaphoresis.<xref ref-type="bibr" rid="article-159922.r69">[69]</xref>&#x000a0;Though opioid withdrawal syndrome is distressing, it has a low association with mortality.</p>
        <p>As an opioid, buprenorphine is also associated with adverse effects from direct mu receptor agonism. These include headache, drowsiness, dizziness, constipation, cognitive impairment, and respiratory depression. The frequency of these adverse effects increases with increasing dose.<xref ref-type="bibr" rid="article-159922.r70">[70]</xref>&#x000a0;Most patients on maintenance therapy buprenorphine-naloxone develop tolerance to the adverse effects of drowsiness, dizziness, sedation, and respiratory depression. However, constipation and miosis are usually still present after months of therapy.<xref ref-type="bibr" rid="article-159922.r71">[71]</xref><xref ref-type="bibr" rid="article-159922.r72">[72]</xref></p>
        <p>Several case reports describe the development of dental caries, tooth erosion, and tooth decay after initiating buprenorphine-naloxone therapy.<xref ref-type="bibr" rid="article-159922.r73">[73]</xref><xref ref-type="bibr" rid="article-159922.r74">[74]</xref>&#x000a0;The mechanism by which buprenorphine-naloxone causes dental damage is uncertain, but it is hypothesized to be associated with the acidity of the dissolved drug.<xref ref-type="bibr" rid="article-159922.r73">[73]</xref><xref ref-type="bibr" rid="article-159922.r75">[75]</xref>&#x000a0;The sublingual film form of buprenorphine-naloxone is associated with hypoesthesia, or numbness, in the area of film dissolution. This is usually temporary and short-lived.</p>
        <p>Opioid-induced hyperalgesia refers to the condition where exposure to prescribed opioids leads to hyperalgesia and allodynia.<xref ref-type="bibr" rid="article-159922.r76">[76]</xref><xref ref-type="bibr" rid="article-159922.r77">[77]</xref>&#x000a0;In 2023, the FDA emphasized the requirement for a new warning regarding opioid-induced hyperalgesia. This phenomenon can potentially arise with prolonged use and higher doses.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Buprenorphine-naloxone should be administered cautiously in patients&#x000a0;prescribed central nervous system depressants such as alcohol, muscle relaxants, and benzodiazepines. Administration of buprenorphine with benzodiazepines&#x000a0;is associated with&#x000a0;acute respiratory deterioration.<xref ref-type="bibr" rid="article-159922.r3">[3]</xref><xref ref-type="bibr" rid="article-159922.r78">[78]</xref><xref ref-type="bibr" rid="article-159922.r79">[79]</xref><xref ref-type="bibr" rid="article-159922.r80">[80]</xref></p>
        <p>Buprenorphine-naloxone therapy may prolong the corrected QT interval (QTc). Patients taking QT-prolonging medications such as antipsychotics, antidepressants, antiarrhythmics, macrolide antibiotics, fluoroquinolone antibiotics, or ondansetron should be monitored with an electrocardiogram during the induction period.</p>
        <p>Buprenorphine-naloxone undergoes significant hepatic metabolism by the cytochrome P450 3A4 enzyme. Dose adjustment may be required for patients taking medications with substantial inhibition of the cytochrome 3A4 enzyme, including macrolide antibiotics, ketoconazole, and protease inhibitors, as these can prolong the duration of action.<xref ref-type="bibr" rid="article-159922.r4">[4]</xref></p>
        <p>Administration of buprenorphine-naloxone with medications possessing anticholinergic properties such as benztropine, oxybutynin, diphenhydramine, scopolamine, antipsychotics, and tricyclic antidepressants can increase the risk for urinary retention and constipation.<xref ref-type="bibr" rid="article-159922.r81">[81]</xref><xref ref-type="bibr" rid="article-159922.r82">[82]</xref></p>
        <p>The coadministration of MAO inhibitors&#x000a0;such as phenelzine, tranylcypromine, and linezolid with opioids, including buprenorphine, may result in serotonin syndrome.<xref ref-type="bibr" rid="article-159922.r83">[83]</xref>&#x000a0;Buprenorphine-naloxone is not advised in patients currently taking MAO inhibitors or within 14 days after discontinuing such treatment.</p>
      </sec>
      <sec id="article-159922.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Box Warning</bold>
</p>
        <p>Buprenorphine-naloxone carries a box warning that it contains an opioid that can be misused, leading to addiction and death. Administration of buprenorphine-naloxone&#x000a0;is associated with fatal respiratory depression.<xref ref-type="bibr" rid="article-159922.r79">[79]</xref>&#x000a0;The risk is increased when buprenorphine-naloxone is used with benzodiazepines and other sedating medications, including alcohol.<xref ref-type="bibr" rid="article-159922.r79">[79]</xref><xref ref-type="bibr" rid="article-159922.r80">[80]</xref>&#x000a0;Buprenorphine-naloxone should be stored in a location not accessible to children, as fatal respiratory depression has been reported.<xref ref-type="bibr" rid="article-159922.r84">[84]</xref>&#x000a0;Buprenorphine-naloxone should not be administered to individuals with known hypersensitivity to any ingredient. Severe hypersensitivity, including anaphylaxis and angioedema, is an absolute contraindication to buprenorphine-naloxone therapy.</p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>There are several relative contraindications to the initiation of buprenorphine-naloxone therapy. Pulmonary and gastrointestinal contraindications include respiratory depression, status asthmaticus, acute bronchospasm, cor pulmonate, mechanical bowel obstruction, and ileus.<xref ref-type="bibr" rid="article-159922.r4">[4]</xref>&#x000a0;Patients with cirrhosis or liver failure require slow titration during the induction period with the recognition that maintenance dose requirements may be lower in this population.&#x000a0;Buprenorphine treatment is generally linked to low rates of serum enzyme elevations, comparable to or less than those observed with methadone, even in populations with coexisting chronic liver diseases. However, acute liver injury has been reported within weeks to months of initiating buprenorphine following misuse via&#x000a0;IV administration of sublingual tablets. This injury typically displays hepatocellular patterns without immune-allergic features and occurs mainly in patients with concurrent chronic hepatitis C. The mechanism&#x000a0;is dose-dependent direct toxicity. Reported cases range from mild to severe hepatitis, occasionally resulting in fatalities. Some patients resumed buprenorphine use without recurrence, including those with a history of&#x000a0;IV misuse.<xref ref-type="bibr" rid="article-159922.r41">[41]</xref></p>
        <p>Relative neurologic contraindications include altered mental status from acute alcohol intoxication, sedative-hypnotics, benzodiazepines, and psychosis from drugs of abuse.<xref ref-type="bibr" rid="article-159922.r79">[79]</xref><xref ref-type="bibr" rid="article-159922.r80">[80]</xref><xref ref-type="bibr" rid="article-159922.r85">[85]</xref>&#x000a0;Buprenorphine-naloxone is also relatively contraindicated after traumatic brain injury because of&#x000a0;its association with respiratory acidosis and increased intracranial pressure. Additionally, the effects of buprenorphine-naloxone, including miosis and depressed mental status, may obscure patient evaluation after traumatic brain injury. Lastly, buprenorphine-naloxone is relatively contraindicated after loss of sympathetic tone, including high spinal cord injury or neuraxial anesthesia, because it can worsen hypotension.</p>
        <p>Adrenal insufficiency, including Addison disease, is a relative contraindication to buprenorphine-naloxone therapy. Chronic buprenorphine-naloxone therapy may worsen adrenal function, leading to symptoms of fatigue, weakness, abdominal pain, anorexia, hypotension, and hyponatremia.<xref ref-type="bibr" rid="article-159922.r86">[86]</xref><xref ref-type="bibr" rid="article-159922.r87">[87]</xref></p>
      </sec>
      <sec id="article-159922.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>All patients undergoing buprenorphine-naloxone induction should have frequent office visits to promote treatment compliance and facilitate early detection of diversion. These visits may include drug testing and medication dose adjustments.<xref ref-type="bibr" rid="article-159922.r35">[35]</xref>&#x000a0;During this vulnerable period, patients should be monitored for signs and symptoms of opioid withdrawal syndrome and severe pain.</p>
        <p>Although pregnancy is not considered a contraindication to buprenorphine-naloxone therapy, &#x003b2;-human chorionic gonadotropin (hCG) testing is recommended before initiating therapy. Some&#x000a0;clinicians prefer buprenorphine over buprenorphine-naloxone in pregnant women. Buprenorphine-naloxone therapy&#x000a0;is associated with hypogonadism.<xref ref-type="bibr" rid="article-159922.r88">[88]</xref><xref ref-type="bibr" rid="article-159922.r89">[89]</xref><xref ref-type="bibr" rid="article-159922.r90">[90]</xref>&#x000a0;Accordingly, it is recommended to assess for evidence of adrenal insufficiency before initiating therapy.</p>
        <p>Buprenorphine-naloxone&#x000a0;is associated with dental decay.<xref ref-type="bibr" rid="article-159922.r73">[73]</xref><xref ref-type="bibr" rid="article-159922.r74">[74]</xref>&#x000a0;Regular, frequent dental appointments are recommended for patients who are on buprenorphine-naloxone maintenance therapy.<xref ref-type="bibr" rid="article-159922.r91">[91]</xref><xref ref-type="bibr" rid="article-159922.r92">[92]</xref>&#x000a0;</p>
        <p>The correlation between buprenorphine-naloxone and hepatitis is unknown. Patients with preexisting liver dysfunction appear to be at increased risk of hepatitis.<xref ref-type="bibr" rid="article-159922.r93">[93]</xref>&#x000a0;Regular alanine transaminase and aspartate transaminase enzyme levels are recommended during the induction period and periodically during maintenance therapy for patients with preexisting liver dysfunction or those at high risk for liver dysfunction&#x000a0;like alcohol use disorder.&#x000a0;</p>
        <p>Buprenorphine-naloxone therapy may prolong the QTc. Patients with long QT syndrome, hypokalemia, hypomagnesemia, or those&#x000a0;prescribed QT-prolonging medications should&#x000a0;undergo&#x000a0;an electrocardiogram during the induction period.</p>
        <p>Patients are at high risk for relapse and opioid-related overdose after halting buprenorphine-naloxone therapy. All-cause mortality and mortality due to opioid overdose increases immediately after cessation of buprenorphine-naloxone therapy.<xref ref-type="bibr" rid="article-159922.r3">[3]</xref><xref ref-type="bibr" rid="article-159922.r94">[94]</xref>&#x000a0;The proportion of mu receptors available for full receptor agonists, such as fentanyl and heroin, increases after buprenorphine-naloxone therapy ceases. During this&#x000a0;vulnerable period, an opioid dose that was previously tolerated may precipitate critical respiratory depression. Follow-up is recommended after halting therapy to monitor for depression, anxiety, and drug-seeking behavior.<xref ref-type="bibr" rid="article-159922.r35">[35]</xref></p>
      </sec>
      <sec id="article-159922.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Buprenorphine overdose typically presents with miosis (eye pupillary constriction), depressed consciousness, and respiratory depression&#x02014;which, if severe, can result in death.<xref ref-type="bibr" rid="article-159922.r95">[95]</xref>&#x000a0;Buprenorphine-naloxone is associated with a much lower likelihood of severe respiratory depression than full mu receptor agonists, such as fentanyl and heroin. Dose-effect studies have found there is a ceiling effect regarding the degree of respiratory depression that buprenorphine can cause.<xref ref-type="bibr" rid="article-159922.r3">[3]</xref><xref ref-type="bibr" rid="article-159922.r19">[19]</xref>&#x000a0;This protective ceiling effect is attenuated when buprenorphine is co-administered with benzodiazepines.<xref ref-type="bibr" rid="article-159922.r1">[1]</xref><xref ref-type="bibr" rid="article-159922.r79">[79]</xref><xref ref-type="bibr" rid="article-159922.r80">[80]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>The treatment for opioid-induced respiratory depression is naloxone and ventilatory support. Patients, caregivers, and members of the social support system should be counseled on recognizing and treating respiratory depression. In the hospital setting, the authors have successfully administered 40 mcg of naloxone every 1 to 2 minutes until respiratory and central nervous system depression abates. Administering naloxone in this manner will decrease the severity of opioid withdrawal symptoms. Naloxone is also available in a prefilled syringe for intramuscular injection and as an over-the-counter nasal spray.<xref ref-type="bibr" rid="article-159922.r96">[96]</xref> Due to&#x000a0;the short duration of action, patients may require repeated doses or the initiation of a naloxone infusion. The combination medication buprenorphine-naloxone is not an appropriate treatment for opioid-induced respiratory depression.</p>
      </sec>
      <sec id="article-159922.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Opioid use disorder is a significant public health problem. Buprenorphine-naloxone is one of the most effective medications to treat opioid use disorder. Coordination of effective interprofessional team communication is essential for patients to safely initiate therapy, decrease harm, reduce the risk of relapse, and ensure care is provided.&#x000a0;</p>
        <p>Social workers, mental health therapists, and psychiatrists serve an instrumental role in identifying patients who may benefit from buprenorphine-naloxone therapy. After therapy has begun, social workers, therapists, and psychiatrists are essential components of the safety net required to monitor for diversion, medication toxicity, withdrawal symptoms, dosing compliance, and concurrent psychiatric disorders.&#x000a0;</p>
        <p>According to section 1262 of the Consolidated Appropriations Act of 2023, all&#x000a0;clinicians with Drug Enforcement Administration (DEA) authority for schedule III medications can prescribe buprenorphine-naloxone. Many state nurse practitioners and physician assistants may prescribe buprenorphine-naloxone to increase access.&#x000a0;Although the prescription of buprenorphine for opioid use disorder requires the clinician to obtain a waiver from Substance Abuse and Mental Health Services (SAMHSA), buprenorphine for chronic pain does not require a waiver.<xref ref-type="bibr" rid="article-159922.r13">[13]</xref> A&#x000a0;study utilized a quasi-experimental design to assess a new 4-hour Medication-Assisted Treatment training program tailored for primary care clinicians as an addition to the standard 8-hour SAMHSA DATA 2000 waiver training.</p>
        <p>Evaluating 183 participants, pretraining and posttraining assessments revealed notable improvements in clinicians' confidence and competence in implementing medication-assisted treatment, indicating the potential efficacy of the supplemental training. Further research to confirm these findings and explore broader policy implications is recommended for wider adoption.<xref ref-type="bibr" rid="article-159922.r97">[97]</xref> These clinicians&#x000a0;are ultimately responsible for ethical considerations like determining who should be treated, ensuring that the patient understands the adverse effects and the benefits of treatment, and obtaining informed consent.</p>
        <p>Pharmacists are essential for assessing drug-drug interactions and providing guidance on the initial dose, maintenance dose, and required dosing adjustments due to changes in organ system function and comorbidities. Nurses are often the first to field patient questions about the dosing regimen and patient concerns related to adverse effects. Laboratory technicians and medical assistants reduce the risk of adverse effects through their role in monitoring organ function. In cases of severe overdose, individuals should be hospitalized in the medical intensive care unit, necessitating supervision by critical care clinicians.</p>
        <p>Successful treatment of opioid use disorder requires interprofessional care coordination.<xref ref-type="bibr" rid="article-159922.r98">[98]</xref>&#x000a0;Each team member must draw upon their unique experiences, knowledge, and skills to create a care plan that minimizes&#x000a0;adverse drug reactions, enhances safety, and increases the likelihood of treatment retention. By leveraging a multidisciplinary approach, personalized care plans can be crafted for patients, mitigating the adverse effects of buprenorphine-naloxone and potentially enhancing the overall quality of life for individuals undergoing treatment.</p>
      </sec>
      <sec id="article-159922.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=159922&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=159922">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/159922/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=159922">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-159922.s10">
        <title>References</title>
        <ref id="article-159922.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ward</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Quaye</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Wilens</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Opioid Use Disorders: Perioperative Management of a Special Population.</article-title>
            <source>Anesth Analg</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>127</volume>
            <issue>2</issue>
            <fpage>539</fpage>
            <page-range>539-547</page-range>
            <pub-id pub-id-type="pmid">29847389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barreveld</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mendelson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Deiling</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Viscusi</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Kohan</surname>
                <given-names>LR</given-names>
              </name>
            </person-group>
            <article-title>Caring for Our Patients With Opioid Use Disorder in the Perioperative Period: A Guide for the Anesthesiologist.</article-title>
            <source>Anesth Analg</source>
            <year>2023</year>
            <month>Sep</month>
            <day>01</day>
            <volume>137</volume>
            <issue>3</issue>
            <fpage>488</fpage>
            <page-range>488-507</page-range>
            <pub-id pub-id-type="pmid">37590794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coe</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lofwall</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations.</article-title>
            <source>J Addict Med</source>
            <year>2019</year>
            <season>Mar/Apr</season>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <page-range>93-103</page-range>
            <pub-id pub-id-type="pmid">30531584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Kumar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Viswanath</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Saadabadi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Buprenorphine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>11</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">29083570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kakko</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Svanborg</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Kreek</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Heilig</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial.</article-title>
            <source>Lancet</source>
            <year>2003</year>
            <month>Feb</month>
            <day>22</day>
            <volume>361</volume>
            <issue>9358</issue>
            <fpage>662</fpage>
            <page-range>662-8</page-range>
            <pub-id pub-id-type="pmid">12606177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gowing</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mbewe</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Buprenorphine for managing opioid withdrawal.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Feb</month>
            <day>21</day>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>CD002025</fpage>
            <pub-id pub-id-type="pmid">28220474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meader</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>A comparison of methadone, buprenorphine and alpha(2) adrenergic agonists for opioid detoxification: a mixed treatment comparison meta-analysis.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2010</year>
            <month>Apr</month>
            <day>01</day>
            <volume>108</volume>
            <issue>1-2</issue>
            <fpage>110</fpage>
            <page-range>110-4</page-range>
            <pub-id pub-id-type="pmid">20074867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ling</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Amass</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shoptaw</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Annon</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Hillhouse</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Babcock</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brigham</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Harrer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muir</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Buchan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Orr</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Woody</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Krejci</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ziedonis</surname>
                <given-names>D</given-names>
              </name>
              <collab>Buprenorphine Study Protocol Group</collab>
            </person-group>
            <article-title>A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.</article-title>
            <source>Addiction</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>100</volume>
            <issue>8</issue>
            <fpage>1090</fpage>
            <page-range>1090-100</page-range>
            <pub-id pub-id-type="pmid">16042639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kantelip</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Gerritsen-van Schieveen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Davani</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Interindividual variability of methadone response: impact of genetic polymorphism.</article-title>
            <source>Mol Diagn Ther</source>
            <year>2008</year>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>109</fpage>
            <page-range>109-24</page-range>
            <pub-id pub-id-type="pmid">18422375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strain</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Stitzer</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Liebson</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Bigelow</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Comparison of buprenorphine and methadone in the treatment of opioid dependence.</article-title>
            <source>Am J Psychiatry</source>
            <year>1994</year>
            <month>Jul</month>
            <volume>151</volume>
            <issue>7</issue>
            <fpage>1025</fpage>
            <page-range>1025-30</page-range>
            <pub-id pub-id-type="pmid">8010359</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jutras-Aswad</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Le Foll</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ahamad</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bruneau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rehm</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wild</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brissette</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gagnon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fikowski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ledjiar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Masse</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Socias</surname>
                <given-names>ME</given-names>
              </name>
              <collab>OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse</collab>
            </person-group>
            <article-title>Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.</article-title>
            <source>Am J Psychiatry</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>179</volume>
            <issue>10</issue>
            <fpage>726</fpage>
            <page-range>726-739</page-range>
            <pub-id pub-id-type="pmid">35702828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baxley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Borsari</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Reavis</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Manuel</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Herbst</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Pennington</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Batki</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Seal</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials.</article-title>
            <source>Addict Behav</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>139</volume>
            <fpage>107589</fpage>
            <pub-id pub-id-type="pmid">36565531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dowell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ragan</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Baldwin</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2022</year>
            <month>Nov</month>
            <day>04</day>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>1</fpage>
            <page-range>1-95</page-range>
            <pub-id pub-id-type="pmid">36327391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khanna</surname>
                <given-names>IK</given-names>
              </name>
              <name>
                <surname>Pillarisetti</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain.</article-title>
            <source>J Pain Res</source>
            <year>2015</year>
            <volume>8</volume>
            <fpage>859</fpage>
            <page-range>859-70</page-range>
            <pub-id pub-id-type="pmid">26672499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dahan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yassen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Romberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sarton</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Teppema</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Olofsen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Danhof</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Buprenorphine induces ceiling in respiratory depression but not in analgesia.</article-title>
            <source>Br J Anaesth</source>
            <year>2006</year>
            <month>May</month>
            <volume>96</volume>
            <issue>5</issue>
            <fpage>627</fpage>
            <page-range>627-32</page-range>
            <pub-id pub-id-type="pmid">16547090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gudin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fudin</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain.</article-title>
            <source>Pain Ther</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-54</page-range>
            <pub-id pub-id-type="pmid">31994020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cowan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Macfarlane</surname>
                <given-names>IR</given-names>
              </name>
            </person-group>
            <article-title>Agonist and antagonist properties of buprenorphine, a new antinociceptive agent.</article-title>
            <source>Br J Pharmacol</source>
            <year>1977</year>
            <month>Aug</month>
            <volume>60</volume>
            <issue>4</issue>
            <fpage>537</fpage>
            <page-range>537-45</page-range>
            <pub-id pub-id-type="pmid">409448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zamani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Hassanian-Moghaddam</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Buprenorphine to reverse respiratory depression from methadone overdose in opioid-dependent patients: a prospective randomized trial.</article-title>
            <source>Crit Care</source>
            <year>2020</year>
            <month>Feb</month>
            <day>07</day>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <pub-id pub-id-type="pmid">32033582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yassen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Olofsen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Romberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sarton</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Teppema</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Danhof</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dahan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>81</volume>
            <issue>1</issue>
            <fpage>50</fpage>
            <page-range>50-8</page-range>
            <pub-id pub-id-type="pmid">17185999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greenwald</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Comer</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Fiellin</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2014</year>
            <month>Nov</month>
            <day>01</day>
            <volume>144</volume>
            <fpage>1</fpage>
            <page-range>1-11</page-range>
            <pub-id pub-id-type="pmid">25179217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Schrier</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dahan</surname>
                <given-names>JDC</given-names>
              </name>
              <name>
                <surname>Boon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sarton</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>van Velzen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Niesters</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dahan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Advances in Reversal Strategies of Opioid-induced Respiratory Toxicity.</article-title>
            <source>Anesthesiology</source>
            <year>2022</year>
            <month>Apr</month>
            <day>01</day>
            <volume>136</volume>
            <issue>4</issue>
            <fpage>618</fpage>
            <page-range>618-632</page-range>
            <pub-id pub-id-type="pmid">34958670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lambert</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential.</article-title>
            <source>Nat Rev Drug Discov</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>7</volume>
            <issue>8</issue>
            <fpage>694</fpage>
            <page-range>694-710</page-range>
            <pub-id pub-id-type="pmid">18670432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mendelson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Upton</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Everhart</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Bioavailability of sublingual buprenorphine.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1997</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-7</page-range>
            <pub-id pub-id-type="pmid">9048270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harris</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Mendelson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Upton</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2004</year>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>329</fpage>
            <page-range>329-40</page-range>
            <pub-id pub-id-type="pmid">15080765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elkader</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sproule</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2005</year>
            <volume>44</volume>
            <issue>7</issue>
            <fpage>661</fpage>
            <page-range>661-80</page-range>
            <pub-id pub-id-type="pmid">15966752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hopp</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mundin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bond</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Low absolute bioavailability of oral naloxone in healthy subjects.</article-title>
            <source>Int J Clin Pharmacol Ther</source>
            <year>2012</year>
            <month>May</month>
            <volume>50</volume>
            <issue>5</issue>
            <fpage>360</fpage>
            <page-range>360-7</page-range>
            <pub-id pub-id-type="pmid">22541841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chiang</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Hawks</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of the combination tablet of buprenorphine and naloxone.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2003</year>
            <month>May</month>
            <day>21</day>
            <volume>70</volume>
            <issue>2 Suppl</issue>
            <fpage>S39</fpage>
            <page-range>S39-47</page-range>
            <pub-id pub-id-type="pmid">12738349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Bigelow</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Strain</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2007</year>
            <month>Oct</month>
            <day>08</day>
            <volume>90</volume>
            <issue>2-3</issue>
            <fpage>261</fpage>
            <page-range>261-9</page-range>
            <pub-id pub-id-type="pmid">17517480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rzasa Lynn</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Galinkin</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Naloxone dosage for opioid reversal: current evidence and clinical implications.</article-title>
            <source>Ther Adv Drug Saf</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-88</page-range>
            <pub-id pub-id-type="pmid">29318006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mistry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Houston</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine.</article-title>
            <source>Drug Metab Dispos</source>
            <year>1987</year>
            <season>Sep-Oct</season>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>710</fpage>
            <page-range>710-7</page-range>
            <pub-id pub-id-type="pmid">2891490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kennedy</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Wessel</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Downer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Raymond</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Osakue</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Merlin</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Liebschutz</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Factors Associated with Long-Term Retention in Buprenorphine-Based Addiction Treatment Programs: a Systematic Review.</article-title>
            <source>J Gen Intern Med</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>332</fpage>
            <page-range>332-340</page-range>
            <pub-id pub-id-type="pmid">33469778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gunderson</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>XQ</given-names>
              </name>
              <name>
                <surname>Fiellin</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Bryan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>FR</given-names>
              </name>
            </person-group>
            <article-title>Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial.</article-title>
            <source>Addict Behav</source>
            <year>2010</year>
            <month>May</month>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>537</fpage>
            <page-range>537-40</page-range>
            <pub-id pub-id-type="pmid">20106601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pearce</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Min</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Piske</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Homayra</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Slaunwhite</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Irvine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGowan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nosyk</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study.</article-title>
            <source>BMJ</source>
            <year>2020</year>
            <month>Mar</month>
            <day>31</day>
            <volume>368</volume>
            <fpage>m772</fpage>
            <pub-id pub-id-type="pmid">32234712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reindel</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>DeAngelis</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ferrara</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Conn</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Corigliano</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>An Exploratory Study of Suboxone (Buprenorphine/Naloxone) Film Splitting: Cutting Methods, Content Uniformity, and Stability.</article-title>
            <source>Int J Pharm Compd</source>
            <year>2019</year>
            <season>May-Jun</season>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>258</fpage>
            <page-range>258-263</page-range>
            <pub-id pub-id-type="pmid">31085795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <article-title>The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update.</article-title>
            <source>J Addict Med</source>
            <year>2020</year>
            <season>Mar/Apr</season>
            <volume>14</volume>
            <issue>2S Suppl 1</issue>
            <fpage>1</fpage>
            <page-range>1-91</page-range>
            <pub-id pub-id-type="pmid">32511106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakouni</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McAnulty</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tatar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Socias</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Le Foll</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ahamad</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jutras-Aswad</surname>
                <given-names>D</given-names>
              </name>
              <collab>OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse</collab>
            </person-group>
            <article-title>Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study.</article-title>
            <source>Am J Addict</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>469</fpage>
            <page-range>469-478</page-range>
            <pub-id pub-id-type="pmid">37308805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weiss</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Potter</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Fiellin</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Byrne</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Connery</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Dickinson</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gardin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Gourevitch</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Haller</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Hasson</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kosinski</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Lindblad</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McCance-Katz</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Provost</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Selzer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Somoza</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Sonne</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.</article-title>
            <source>Arch Gen Psychiatry</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>68</volume>
            <issue>12</issue>
            <fpage>1238</fpage>
            <page-range>1238-46</page-range>
            <pub-id pub-id-type="pmid">22065255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fareed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vayalapalli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Casarella</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Drexler</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Effect of buprenorphine dose on treatment outcome.</article-title>
            <source>J Addict Dis</source>
            <year>2012</year>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-18</page-range>
            <pub-id pub-id-type="pmid">22356665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ling</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Charuvastra</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Batki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Kintaudi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wesson</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>McNicholas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tusel</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Malkerneker</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Renner</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Casadonte</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fye</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stine</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial.</article-title>
            <source>Addiction</source>
            <year>1998</year>
            <month>Apr</month>
            <volume>93</volume>
            <issue>4</issue>
            <fpage>475</fpage>
            <page-range>475-86</page-range>
            <pub-id pub-id-type="pmid">9684386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nava</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Manzato</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leonardi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lucchini</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Opioid maintenance therapy suppresses alcohol intake in heroin addicts with alcohol dependence: preliminary results of an open randomized study.</article-title>
            <source>Prog Neuropsychopharmacol Biol Psychiatry</source>
            <year>2008</year>
            <month>Dec</month>
            <day>12</day>
            <volume>32</volume>
            <issue>8</issue>
            <fpage>1867</fpage>
            <page-range>1867-72</page-range>
            <pub-id pub-id-type="pmid">18801404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r41">
          <label>41</label>
          <element-citation publication-type="book">
            <chapter-title>Buprenorphine</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>11</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">31644178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <article-title>Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>130</volume>
            <issue>2</issue>
            <fpage>e81</fpage>
            <page-range>e81-e94</page-range>
            <pub-id pub-id-type="pmid">28742676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <collab>ACOG Committee on Health Care for Underserved Women</collab>
            <collab>American Society of Addiction Medicine</collab>
            <article-title>ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2012</year>
            <month>May</month>
            <volume>119</volume>
            <issue>5</issue>
            <fpage>1070</fpage>
            <page-range>1070-6</page-range>
            <pub-id pub-id-type="pmid">22525931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ecker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Abuhamad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bailit</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bateman</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Berghella</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Blake-Lamb</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Guille</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Landau</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Minkoff</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Prabhu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Terplan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Yonkers</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Substance use disorders in pregnancy: clinical,&#x000a0;ethical, and research imperatives of&#x000a0;the&#x000a0;opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>221</volume>
            <issue>1</issue>
            <fpage>B5</fpage>
            <page-range>B5-B28</page-range>
            <pub-id pub-id-type="pmid">30928567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Link</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Kaltenbach</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Seligman</surname>
                <given-names>NS</given-names>
              </name>
            </person-group>
            <article-title>Buprenorphine-naloxone use in pregnancy: a subgroup analysis of medication to treat opioid use disorder.</article-title>
            <source>Am J Obstet Gynecol MFM</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>3</volume>
            <issue>5</issue>
            <fpage>100369</fpage>
            <pub-id pub-id-type="pmid">33831585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Minozzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Amato</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jahanfar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bellisario</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ferri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Davoli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Maintenance agonist treatments for opiate-dependent pregnant women.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2020</year>
            <month>Nov</month>
            <day>09</day>
            <volume>11</volume>
            <issue>11</issue>
            <fpage>CD006318</fpage>
            <pub-id pub-id-type="pmid">33165953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Meltzer-Brody</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Evaluation and management of opioid dependence in pregnancy.</article-title>
            <source>Psychosomatics</source>
            <year>2012</year>
            <season>Sep-Oct</season>
            <volume>53</volume>
            <issue>5</issue>
            <fpage>424</fpage>
            <page-range>424-32</page-range>
            <pub-id pub-id-type="pmid">22902085</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Desmond</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Wait</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Follow-up of methadone-treated and untreated narcotic-dependent women and their infants: health, developmental, and social implications.</article-title>
            <source>J Pediatr</source>
            <year>1981</year>
            <month>May</month>
            <volume>98</volume>
            <issue>5</issue>
            <fpage>716</fpage>
            <page-range>716-22</page-range>
            <pub-id pub-id-type="pmid">6164775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zedler</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Amick</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Joyce</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Murrelle</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>HE</given-names>
              </name>
            </person-group>
            <article-title>Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child.</article-title>
            <source>Addiction</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>111</volume>
            <issue>12</issue>
            <fpage>2115</fpage>
            <page-range>2115-2128</page-range>
            <pub-id pub-id-type="pmid">27223595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ordean</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tubman-Broeren</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Safety and Efficacy of Buprenorphine-Naloxone in Pregnancy: A Systematic Review of the Literature.</article-title>
            <source>Pathophysiology</source>
            <year>2023</year>
            <month>Feb</month>
            <day>11</day>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-36</page-range>
            <pub-id pub-id-type="pmid">36810423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Link</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kaltenbach</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Seligman</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Buprenorphine-naloxone use in pregnancy: a&#x000a0;systematic review and metaanalysis.</article-title>
            <source>Am J Obstet Gynecol MFM</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>100179</fpage>
            <pub-id pub-id-type="pmid">33345863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiegand</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Swortwood</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Huestis</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Thorp</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Vora</surname>
                <given-names>NL</given-names>
              </name>
            </person-group>
            <article-title>Naloxone and Metabolites Quantification in Cord Blood of Prenatally Exposed Newborns and Correlations with Maternal Concentrations.</article-title>
            <source>AJP Rep</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>e385</fpage>
            <page-range>e385-e390</page-range>
            <pub-id pub-id-type="pmid">27896019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dow</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ordean</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murphy-Oikonen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Roukema</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Selby</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>R</given-names>
              </name>
              <collab>Neonatal Abstinence Syndrome Work Group</collab>
            </person-group>
            <article-title>Neonatal abstinence syndrome clinical practice guidelines for Ontario.</article-title>
            <source>J Popul Ther Clin Pharmacol</source>
            <year>2012</year>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>e488</fpage>
            <page-range>e488-506</page-range>
            <pub-id pub-id-type="pmid">23241498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kakko</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Heilig</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sarman</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2008</year>
            <month>Jul</month>
            <day>01</day>
            <volume>96</volume>
            <issue>1-2</issue>
            <fpage>69</fpage>
            <page-range>69-78</page-range>
            <pub-id pub-id-type="pmid">18355989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piske</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Homayra</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Min</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Marchand</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mead</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Woolner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nosyk</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Opioid Use Disorder and Perinatal Outcomes.</article-title>
            <source>Pediatrics</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>148</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">34479983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r56">
          <label>56</label>
          <element-citation publication-type="book">
            <chapter-title>Buprenorphine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jansson</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>McConnell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Velez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gomonit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Swortwood</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Buprenorphine-Naloxone Maintenance and Lactation.</article-title>
            <source>J Hum Lact</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>113</fpage>
            <page-range>113-119</page-range>
            <pub-id pub-id-type="pmid">38018534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r58">
          <label>58</label>
          <element-citation publication-type="book">
            <chapter-title>Naloxone</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Compton</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Charuvastra</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2001</year>
            <month>Jul</month>
            <day>01</day>
            <volume>63</volume>
            <issue>2</issue>
            <fpage>139</fpage>
            <page-range>139-46</page-range>
            <pub-id pub-id-type="pmid">11376918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wachholtz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Co-morbid pain and opioid addiction: long term effect of opioid maintenance on acute pain.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2014</year>
            <month>Dec</month>
            <day>01</day>
            <volume>145</volume>
            <fpage>143</fpage>
            <page-range>143-9</page-range>
            <pub-id pub-id-type="pmid">25456326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matthews</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dwyer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Snoek</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Stigma and Self-Stigma in Addiction.</article-title>
            <source>J Bioeth Inq</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>275</fpage>
            <page-range>275-286</page-range>
            <pub-id pub-id-type="pmid">28470503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Katznelson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Perrot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Perioperative management of a patient undergoing Clagett window closure stabilized on Suboxone&#x000ae; for chronic pain: a case report.</article-title>
            <source>Can J Anaesth</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>61</volume>
            <issue>9</issue>
            <fpage>826</fpage>
            <page-range>826-31</page-range>
            <pub-id pub-id-type="pmid">24985936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCormick</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Chang-Chien</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Acute pain control challenges with buprenorphine/naloxone therapy in a patient with compartment syndrome secondary to McArdle's disease: a case report and review.</article-title>
            <source>Pain Med</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>8</issue>
            <fpage>1187</fpage>
            <page-range>1187-91</page-range>
            <pub-id pub-id-type="pmid">23647815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lamba</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Nothing About Us Without Us: A Solution to Iatrogenic Perioperative Morbidity and Mortality in People Who Use Drugs.</article-title>
            <source>Anesth Analg</source>
            <year>2023</year>
            <month>Sep</month>
            <day>01</day>
            <volume>137</volume>
            <issue>3</issue>
            <fpage>470</fpage>
            <page-range>470-473</page-range>
            <pub-id pub-id-type="pmid">37590792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hansen</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Matson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Tybor</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Pevear</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>Total Joint Arthroplasty in Patients Taking Methadone or Buprenorphine/Naloxone Preoperatively for Prior Heroin Addiction: A Prospective Matched Cohort Study.</article-title>
            <source>J Arthroplasty</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>31</volume>
            <issue>8</issue>
            <fpage>1698</fpage>
            <page-range>1698-701</page-range>
            <pub-id pub-id-type="pmid">26899477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Macintyre</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Usher</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Gaughwin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huxtable</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Pain relief and opioid requirements in the first 24 hours after surgery in patients taking buprenorphine and methadone opioid substitution therapy.</article-title>
            <source>Anaesth Intensive Care</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>222</fpage>
            <page-range>222-30</page-range>
            <pub-id pub-id-type="pmid">23530789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Volpe</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>McMahon Tobin</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Mellon</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Katki</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Colatsky</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kropp</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Verbois</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Uniform assessment and ranking of opioid &#x003bc; receptor binding constants for selected opioid drugs.</article-title>
            <source>Regul Toxicol Pharmacol</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>59</volume>
            <issue>3</issue>
            <fpage>385</fpage>
            <page-range>385-90</page-range>
            <pub-id pub-id-type="pmid">21215785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alford</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Compton</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Samet</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Acute pain management for patients receiving maintenance methadone or buprenorphine therapy.</article-title>
            <source>Ann Intern Med</source>
            <year>2006</year>
            <month>Jan</month>
            <day>17</day>
            <volume>144</volume>
            <issue>2</issue>
            <fpage>127</fpage>
            <page-range>127-34</page-range>
            <pub-id pub-id-type="pmid">16418412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Donroe</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Holt</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Tetrault</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Caring for patients with opioid use disorder in the hospital.</article-title>
            <source>CMAJ</source>
            <year>2016</year>
            <month>Dec</month>
            <day>06</day>
            <volume>188</volume>
            <issue>17-18</issue>
            <fpage>1232</fpage>
            <page-range>1232-1239</page-range>
            <pub-id pub-id-type="pmid">27647616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swegle</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Logemann</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Management of common opioid-induced adverse effects.</article-title>
            <source>Am Fam Physician</source>
            <year>2006</year>
            <month>Oct</month>
            <day>15</day>
            <volume>74</volume>
            <issue>8</issue>
            <fpage>1347</fpage>
            <page-range>1347-54</page-range>
            <pub-id pub-id-type="pmid">17087429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freye</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Latasch</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>[Development of opioid tolerance -- molecular mechanisms and clinical consequences].</article-title>
            <source>Anasthesiol Intensivmed Notfallmed Schmerzther</source>
            <year>2003</year>
            <month>Jan</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <page-range>14-26</page-range>
            <pub-id pub-id-type="pmid">12522725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farmer</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Drewes</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Chiarioni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Giorgio</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Morlion</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tack</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology and management of opioid-induced constipation: European expert consensus statement.</article-title>
            <source>United European Gastroenterol J</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-20</page-range>
            <pub-id pub-id-type="pmid">30788113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suzuki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Sublingual buprenorphine and dental problems: a case series.</article-title>
            <source>Prim Care Companion CNS Disord</source>
            <year>2013</year>
            <volume>15</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">24511440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Titsas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Impact of opioid use on dentistry.</article-title>
            <source>Aust Dent J</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>94</fpage>
            <page-range>94-8</page-range>
            <pub-id pub-id-type="pmid">12139280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Etminan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rezaeianzadeh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kezouh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aminzadeh</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Association Between Sublingual Buprenorphine-Naloxone Exposure and Dental Disease.</article-title>
            <source>JAMA</source>
            <year>2022</year>
            <month>Dec</month>
            <day>13</day>
            <volume>328</volume>
            <issue>22</issue>
            <fpage>2269</fpage>
            <page-range>2269-2271</page-range>
            <pub-id pub-id-type="pmid">36511932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Hellman</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Adler</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Chandrakantan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms, diagnosis, prevention&#x000a0;and management of perioperative opioid-induced hyperalgesia.</article-title>
            <source>Pain Manag</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>405</fpage>
            <page-range>405-417</page-range>
            <pub-id pub-id-type="pmid">33779215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>VB</given-names>
              </name>
              <name>
                <surname>Manchikanti</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>A comprehensive review of opioid-induced hyperalgesia.</article-title>
            <source>Pain Physician</source>
            <year>2011</year>
            <season>Mar-Apr</season>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>145</fpage>
            <page-range>145-61</page-range>
            <pub-id pub-id-type="pmid">21412369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nielsen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dietze</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dunlop</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment.</article-title>
            <source>Addiction</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>102</volume>
            <issue>4</issue>
            <fpage>616</fpage>
            <page-range>616-22</page-range>
            <pub-id pub-id-type="pmid">17286641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tracqui</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kintz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ludes</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities.</article-title>
            <source>J Anal Toxicol</source>
            <year>1998</year>
            <month>Oct</month>
            <volume>22</volume>
            <issue>6</issue>
            <fpage>430</fpage>
            <page-range>430-4</page-range>
            <pub-id pub-id-type="pmid">9788517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Larochelle</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Saitz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bernson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Walley</surname>
                <given-names>AY</given-names>
              </name>
            </person-group>
            <article-title>Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.</article-title>
            <source>Addiction</source>
            <year>2020</year>
            <month>May</month>
            <volume>115</volume>
            <issue>5</issue>
            <fpage>924</fpage>
            <page-range>924-932</page-range>
            <pub-id pub-id-type="pmid">31916306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chokhavatia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Bridgeman</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Dixit</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Constipation in Elderly Patients with Noncancer Pain: Focus on Opioid-Induced Constipation.</article-title>
            <source>Drugs Aging</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>33</volume>
            <issue>8</issue>
            <fpage>557</fpage>
            <page-range>557-74</page-range>
            <pub-id pub-id-type="pmid">27417446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verhamme</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Sturkenboom</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Stricker</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced urinary retention: incidence, management and prevention.</article-title>
            <source>Drug Saf</source>
            <year>2008</year>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>373</fpage>
            <page-range>373-88</page-range>
            <pub-id pub-id-type="pmid">18422378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edinoff</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Swinford</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Odisho</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Burroughs</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Stark</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Raslan</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Cornett</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors.</article-title>
            <source>Health Psychol Res</source>
            <year>2022</year>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>39576</fpage>
            <pub-id pub-id-type="pmid">36425231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Smiddy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure.</article-title>
            <source>Pediatrics</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>130</volume>
            <issue>6</issue>
            <fpage>e1700</fpage>
            <page-range>e1700-3</page-range>
            <pub-id pub-id-type="pmid">23129079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nagappa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Abrahamyan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>FF</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for opioid-induced respiratory depression and failure to rescue: a review.</article-title>
            <source>Curr Opin Anaesthesiol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>110</fpage>
            <page-range>110-119</page-range>
            <pub-id pub-id-type="pmid">29120929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r86">
          <label>86</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Munir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Quintanilla Rodriguez</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Waseem</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Addison Disease</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>1</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">28723023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coluzzi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>LeQuang</surname>
                <given-names>JAK</given-names>
              </name>
              <name>
                <surname>Sciacchitano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Scerpa</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Rocco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pergolizzi</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A Closer Look at Opioid-Induced Adrenal Insufficiency: A Narrative Review.</article-title>
            <source>Int J Mol Sci</source>
            <year>2023</year>
            <month>Feb</month>
            <day>26</day>
            <volume>24</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">36902007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brennan</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>The effect of opioid therapy on endocrine function.</article-title>
            <source>Am J Med</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>126</volume>
            <issue>3 Suppl 1</issue>
            <fpage>S12</fpage>
            <page-range>S12-8</page-range>
            <pub-id pub-id-type="pmid">23414717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daniell</surname>
                <given-names>HW</given-names>
              </name>
            </person-group>
            <article-title>Hypogonadism in men consuming sustained-action oral opioids.</article-title>
            <source>J Pain</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>3</volume>
            <issue>5</issue>
            <fpage>377</fpage>
            <page-range>377-84</page-range>
            <pub-id pub-id-type="pmid">14622741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meczekalski</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Podfigurna-Stopa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Warenik-Szymankiewicz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Genazzani</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Functional hypothalamic amenorrhea: current view on neuroendocrine aberrations.</article-title>
            <source>Gynecol Endocrinol</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-11</page-range>
            <pub-id pub-id-type="pmid">18224538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Viswanath</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barreveld</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Fortino</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Assessment and Management of the High-Risk Dental Patient with Active Substance Use Disorder.</article-title>
            <source>Dent Clin North Am</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>64</volume>
            <issue>3</issue>
            <fpage>547</fpage>
            <page-range>547-558</page-range>
            <pub-id pub-id-type="pmid">32448458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yazdanian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Armoon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Noroozi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mohammadi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bayat</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Ahounbar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Higgs</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nasab</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Bayani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hemmat</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Dental caries and periodontal disease among people who use drugs: a systematic review and meta-analysis.</article-title>
            <source>BMC Oral Health</source>
            <year>2020</year>
            <month>Feb</month>
            <day>10</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <pub-id pub-id-type="pmid">32041585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zuin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giorgini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Selmi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Battezzati</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Cocchi</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Crosignani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Benetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Invernizzi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Podda</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Acute liver and renal failure during treatment with buprenorphine at therapeutic dose.</article-title>
            <source>Dig Liver Dis</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>41</volume>
            <issue>7</issue>
            <fpage>e8</fpage>
            <page-range>e8-e10</page-range>
            <pub-id pub-id-type="pmid">18294936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sordo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Barrio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bravo</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Indave</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Degenhardt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wiessing</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ferri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pastor-Barriuso</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.</article-title>
            <source>BMJ</source>
            <year>2017</year>
            <month>Apr</month>
            <day>26</day>
            <volume>357</volume>
            <fpage>j1550</fpage>
            <pub-id pub-id-type="pmid">28446428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palkovic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Callison</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Marchenko</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Stuth</surname>
                <given-names>EAE</given-names>
              </name>
              <name>
                <surname>Zuperku</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Stucke</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Dose-dependent Respiratory Depression by Remifentanil in the Rabbit Parabrachial Nucleus/K&#x000f6;lliker-Fuse Complex and Pre-B&#x000f6;tzinger Complex.</article-title>
            <source>Anesthesiology</source>
            <year>2021</year>
            <month>Oct</month>
            <day>01</day>
            <volume>135</volume>
            <issue>4</issue>
            <fpage>649</fpage>
            <page-range>649-672</page-range>
            <pub-id pub-id-type="pmid">34352068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Avetian</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Fiuty</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mazzella</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koppa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Heye</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hebbar</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Use of naloxone nasal spray 4&#x02009;mg in the community setting: a survey of use by community organizations.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>573</fpage>
            <page-range>573-576</page-range>
            <pub-id pub-id-type="pmid">28535115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gardner-Buckshaw</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Perzynski</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Spieth</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Khaira</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Delos Reyes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kropp</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Caron</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boltri</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Increasing Primary Care Utilization of Medication-Assisted Treatment (MAT) for Opioid Use Disorder.</article-title>
            <source>J Am Board Fam Med</source>
            <year>2023</year>
            <month>Apr</month>
            <day>03</day>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>251</fpage>
            <page-range>251-266</page-range>
            <pub-id pub-id-type="pmid">36948541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159922.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jimenez Ruiz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Warner</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Acampora</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kohan</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Substance Use Disorders: Basic Overview for the Anesthesiologist.</article-title>
            <source>Anesth Analg</source>
            <year>2023</year>
            <month>Sep</month>
            <day>01</day>
            <volume>137</volume>
            <issue>3</issue>
            <fpage>508</fpage>
            <page-range>508-520</page-range>
            <pub-id pub-id-type="pmid">37590795</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
